Selected for the '2026 Innovation Premier 1000' Project
Accelerating Global Commercialization

DaimBio announced on the 24th that it has been finally selected as an innovative company in the bio sector by the Ministry of Health and Welfare, as part of the government's '2026 Innovation Premier 1000' project. The company was recognized for its competitiveness in developing anticancer drugs based on BBB (Blood-Brain Barrier) permeability and novel therapeutics for degenerative brain diseases based on its TASR (Taste Receptor) platform.


DaimBio Recognized as 'Innovative Company' for BBB-Permeable Anticancer Drugs and Novel Brain Disease Therapeutics Development View original image

The Innovation Premier 1000 is a government-led corporate development program that selects promising companies with innovation and growth potential and provides support such as financial assistance, investment attraction, overseas expansion, business capability enhancement, and technology protection. By being selected, DaimBio will be able to accelerate its research and development and global commercialization utilizing a variety of government support programs.


DaimBio is developing innovative new drugs, including anticancer and degenerative brain disease therapeutics, based on its BBB permeability-based small-molecule drug synthesis technology and the TASR platform. Its lead pipeline candidate, 'DM5167', is a next-generation PARP1-selective inhibitor with excellent BBB permeability, offering the possibility to expand indications not only for existing solid tumors but also for brain metastases. Currently, the company is conducting Phase 1 clinical trials in cancer patients in Korea and has confirmed superior hematologic safety compared to other PARP inhibitors. DaimBio plans to conduct follow-up clinical trials with the US Food and Drug Administration (FDA) and pursue global technology transfer, thereby expanding its entry into overseas markets.


In the degenerative brain disease sector, DaimBio is developing the TASR platform-based Alzheimer's drug 'DM3159' and the Parkinson's disease treatment 'DM3190'. DM3159 demonstrated efficacy in preclinical studies and is slated to undergo GLP toxicology testing later this year, with the goal of obtaining global Phase 1 IND approval next year. DM3190 is also continuing its preclinical research, thereby expanding the company's central nervous system (CNS) pipeline.



Jungmin Kim, CEO of DaimBio, stated, "Our selection for the 2026 Innovation Premier 1000 is a meaningful achievement that recognizes our innovative new drug development technology and growth potential. Leveraging government support, we will accelerate next-generation new drug development and expand global clinical trials, technology transfer, and overseas market entry to establish ourselves as a leading global bio company."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing